Buy retatrutide UK 2026 — the TRIUMPH-1 data, 28.3% weight loss, and what it means for buyers right now

If you have been following the GLP-1 space for the last two years, the May 2026 TRIUMPH-1 readout is the moment everyone was waiting for. The Phase 2 data hinted at something genuinely different. The Phase 3 data has now confirmed it. Whether you came to this page to understand the numbers or to figure out how to buy retatrutide in the UK right now, this is the breakdown you actually need — not the press-release copy. We cover the data, the side effects, the realistic UK availability timeline, and exactly how to buy retatrutide today if you decide that is the right move for you.

What actually happened on 21 May 2026

Four days ago, Eli Lilly — the pharmaceutical company that already owns the dominant tirzepatide brand — released the topline results of TRIUMPH-1, its first major registrational Phase 3 trial of retatrutide in adults with obesity. Within hours, search interest from people looking to buy retatrutide in the UK and Europe spiked to its highest level in 18 months.

This was the trial the entire metabolic-health space had been pointing at since the Phase 2 results were published in The New England Journal of Medicine in 2023. The Phase 2 numbers were already startling, and they drove the first major wave of UK buyers looking to buy retatrutide outside the licensed-medicine route. The question for TRIUMPH-1 was whether those Phase 2 numbers would hold up in a much larger, longer Phase 3 trial — the kind of trial regulators actually use to approve medicines.

The answer is yes. The numbers didn't just hold — they got bigger.

TRIUMPH-1 enrolled 2,339 participants with obesity, randomised across four arms: retatrutide 4 mg, 9 mg, 12 mg, or placebo. Doses were built up gradually every four weeks from a 2 mg starting point. The trial ran for 80 weeks, with a 24-week extension for participants who tolerated the 9 mg or 12 mg dose.

The numbers reported on 21 May 2026:

• 4 mg dose: 17.6% average body weight loss at 80 weeks
• 9 mg dose: 23.7% average body weight loss at 80 weeks
• 12 mg dose: 25.0% average body weight loss at 80 weeks — rising to 28.3% on the efficacy estimand
• Placebo: 3.9% average body weight loss at 80 weeks

And then the extension cohort — 532 participants with starting BMI ≥35, escalated to their maximum tolerated dose for another 24 weeks — lost an average of 30.3% of their body weight at 104 weeks. That is roughly a third of their starting body weight, lost over two years on a once-weekly injection.

The headline numbers — and what's hidden inside them

Big topline figures hide as much as they reveal. The really telling parts of TRIUMPH-1 are the secondary endpoints, not the average.

The "no plateau" finding

The single most striking observation from the trial is what didn't happen: participants didn't stop losing weight. In every previous large weight-loss trial — semaglutide's STEP programme, tirzepatide's SURMOUNT trials — the curve flattens somewhere between months 12 and 18. The body adjusts; weight loss stabilises; further loss requires further intervention.

In TRIUMPH-1, the weight-loss curve was still descending at 80 weeks. The extension cohort confirmed it: pushed out to 104 weeks, the curve kept going. This is the first weight-loss drug where the answer to "how long can you stay on it before the effect levels off?" appears to be much longer than the trial duration.

The ≥30% threshold

The headline that has been everywhere in the medical press: 45.3% of participants on the 12 mg dose achieved at least 30% body weight loss. To put that in context, 30% body weight loss is the threshold historically associated with bariatric (weight-loss) surgery. Anything pharmaceutical that gets close to that figure is genuinely new. Anything that puts nearly half the trial population past it is, in clinical terms, a category shift.

Cardiometabolic improvements

Underneath the weight numbers sit the metabolic markers, which often matter more than the scale figure for long-term health:

• Waist circumference reduction of 24.1 cm (9.5 inches) on average at 12 mg — a marker of visceral fat reduction, the metabolically dangerous kind
• Reductions in non-HDL cholesterol and triglycerides
• Reduction in systolic blood pressure
• Reduction in high-sensitivity C-reactive protein — a marker of systemic inflammation

Each of these on its own would be an interesting finding. Stacked, they describe a metabolic profile shift, not just a body composition shift.

Why the 45.3% figure is a watershed moment

It is worth pausing on this number specifically, because it is the one that changes how the entire obesity-treatment field thinks about pharmacotherapy.

Until very recently, the implicit understanding among clinicians was simple: if a patient needed to lose more than 25-30% of their body weight, pharmacotherapy alone was not enough. Surgery was the only route. Drugs were for the "less severe" end of obesity; surgery was for the "more severe" end.

Tirzepatide started to erode that line. Retatrutide, with TRIUMPH-1, has effectively erased it. When nearly half of trial participants on the highest dose cross the 30% threshold — without surgery, without major lifestyle interventions described as the dominant variable, just a once-weekly injection — the clinical framing shifts.

This matters for UK readers in two specific ways. First, it changes what counts as a reasonable expectation when discussing weight-loss medication with a clinician. Second, it changes the economic case for NICE: a drug that produces surgery-grade outcomes without surgery's overhead is a different calculation than one that produces modest weight loss. Third — and this is the practical one — it explains why the demand to buy retatrutide in the UK has already outrun the licensed-medicine timeline.

Why retatrutide works differently to Mounjaro and Wegovy

The reason TRIUMPH-1 produced these numbers is not luck. It is mechanism. Understanding it in one sentence is worth two minutes of reading.

Semaglutide (sold as Wegovy in the UK weight-loss indication) acts on one receptor — GLP-1. Tirzepatide (Mounjaro) acts on two — GLP-1 and GIP. Retatrutide acts on three — GLP-1, GIP, and glucagon.

The GLP-1 pathway primarily reduces appetite and slows gastric emptying. Adding GIP, as tirzepatide does, contributes additional insulin and fat metabolism effects. Adding glucagon, as retatrutide does, is the one that changes the picture: glucagon receptor activity can increase energy expenditure. In simple terms, where the previous generations told the body to eat less, retatrutide tells the body to both eat less and burn more.

That is the mechanistic explanation for why retatrutide produces larger trial outcomes, and why the weight-loss curve does not plateau in the same way. It is also the reason a growing share of UK readers researching the GLP-1 space ultimately decide to buy retatrutide rather than stay on tirzepatide or semaglutide. You can read a deeper breakdown of all three peptides in our retatrutide vs tirzepatide vs semaglutide comparison.

The full trial data — doses, outcomes and side effects

This is the level of detail most press coverage skips. Anyone making a real decision about whether to wait for licensed retatrutide or buy retatrutide through the UK wellness-product market needs to see it in full.

TRIUMPH-1 efficacy table

The side-effect profile

The honest picture: retatrutide produces the largest outcomes and the highest discontinuation rates in the class. Both are dose-dependent.

From TRIUMPH-1, discontinuation rates due to adverse events were:

• 4 mg: 4.1% — in line with placebo (4.9%)
• 9 mg: 6.9%
• 12 mg: 11.3%

The specific side effects mirror the rest of the GLP-1 class — they are gastrointestinal. From the earlier TRANSCEND-T2D-1 Phase 3 trial in March 2026:

• Nausea: 26.5% on the highest dose
• Diarrhoea: 22.8% on the highest dose
• Vomiting: 17.6% on the highest dose

A small number of participants also experienced dysesthesia, an unpleasant nerve sensation. Modest increases in heart rate — a known feature of the class — were also observed.

The TRIUMPH-4 osteoarthritis data — a reminder

One thing worth flagging from TRIUMPH-4 (published December 2025), because it gets less coverage than the weight-loss numbers: in participants with obesity and knee osteoarthritis, retatrutide 12 mg produced an average 75.8% reduction in WOMAC pain scores, with more than one in eight participants ending the trial completely free of knee pain. The mechanism is presumed to be a combination of weight reduction and direct anti-inflammatory effect from the glucagon pathway.

Retatrutide vs Mounjaro vs Wegovy — the head-to-head no one shows you

Before deciding whether to buy retatrutide, most UK readers want to see how it compares to the licensed alternatives. Direct head-to-head trials between retatrutide and the licensed alternatives do not yet exist. But we now have enough published Phase 3 data on all three to compare the best published outcomes for each, on the metric people care about most.

The structural picture is clear: retatrutide produces materially larger outcomes on every weight-loss metric, but sits in a different regulatory bracket. It is not a question of whether it is "better." It is a question of which trade-off makes sense for which buyer — and, for buyers ready to act now, whether the right move is to buy retatrutide via the wellness-product route or wait for licensed retatrutide via prescription.

When will retatrutide be available in the UK?

This is the question UK readers want answered the most, and it sits underneath every search for "buy retatrutide UK" right now. The answer needs to be honest about uncertainty.

Eli Lilly has not announced a regulatory filing date for retatrutide in any jurisdiction. The TRIUMPH-1 data is one of nine Phase 3 trials in the programme; the other seven are reading out through the rest of 2026, with TRIUMPH-2, TRIUMPH-3 and TRIUMPH-5 among the most-watched. A regulatory submission would typically come after the bulk of the programme has reported, which points to a filing in late 2026 or 2027 at the earliest.

The realistic UK timeline from there:

If you compress the most optimistic version of every step, retatrutide on private UK prescription could land in late 2027. The realistic central estimate is 2028. NHS access on top of that, perhaps 2028–2029, and even then only for narrowly defined patient groups initially. That gap — between the data being public now and licensed access being two-to-three years out — is exactly why a parallel UK market has emerged where adults 18+ can buy retatrutide as a premium wellness product.

The NHS question — what NICE approval really looks like

UK readers who watched what happened with tirzepatide on the NHS already know the pattern, but it is worth spelling it out, because the same pattern almost certainly applies to retatrutide.

NHS access in the UK is a two-stage process. Stage one is MHRA marketing authorisation — the regulator decides the drug is safe and effective enough to be sold in the UK. Stage two is NICE technology appraisal — the body that decides whether the NHS will pay for it.

NICE looks at cost-effectiveness, not just clinical efficacy. The bigger the patient population, the more carefully they price what counts as cost-effective. For tirzepatide, NICE eventually approved NHS use, but with a phased rollout that prioritised the highest-BMI patients with metabolic complications. The same logic almost certainly applies to retatrutide, which is more expensive to manufacture and will likely be more expensive per dose.

Practical implication: even after retatrutide is approved by the MHRA and through NICE, the average UK adult wanting it for general weight management is more likely to access it privately than via their GP, at least for the first two to three years after launch. NHS access will be available, but tightly restricted at the start.

Should you wait for licensed retatrutide, or buy retatrutide now?

This is the question this whole article exists to help with, and it is the question Google sees most often when people search "buy retatrutide" in 2026. There is no universal answer; the right call depends on which of three buyer profiles you fit.

Profile A: "I'm not in a hurry — I'd rather have the fully licensed product"

If your priority is the regulated medicine route and you are prepared to wait, the right move is patience — do not buy retatrutide today. Track Lilly's Phase 3 readouts through the rest of 2026, follow MHRA news in 2027, and revisit the question when private prescription access opens. In the meantime, licensed tirzepatide or semaglutide are reasonable interim options through regulated UK pharmacies.

Profile B: "I want to buy retatrutide now and I'm comfortable with the wellness-product route"

If you are 18 or over, UK-resident, and comfortable with the fact that retatrutide is currently sold in the UK as a premium wellness product rather than a licensed medicine, this is the route a growing number of UK buyers are taking. Brands like Retapen40 sell UK-finished retatrutide pens in this market, which means you can buy retatrutide today with free tracked UK delivery, cold-chain packaging and a 60-day satisfaction guarantee. You are buying outside the regulated-medicine system, with the trade-offs that come with that — no GP oversight, no NICE-approved indications, no prescription. You are also accessing the newest peptide in the class roughly two to three years before its likely MHRA approval. If you've decided to buy retatrutide via this route, the UK buy guide walks through the six checks to run before placing your first order.

Profile C: "I'm not sure yet"

The honest answer for Profile C is that there is no rush to decide. The TRIUMPH-1 data isn't going anywhere. The remaining seven Phase 3 readouts will sharpen the long-term safety picture meaningfully over the next 6–12 months. Watch the headlines, watch what NICE signals, and revisit whether you want to buy retatrutide once you have a clearer read on your own priorities.

What comes next — the seven remaining TRIUMPH trials

TRIUMPH-1 was the first big obesity readout, but it is part of a much bigger Phase 3 programme. Seven more trials are still to report through 2026. Each one will sharpen the picture in a different direction.

• TRIUMPH-2 — Retatrutide for weight management in type 2 diabetes
• TRIUMPH-3 — Head-to-head against dulaglutide in type 2 diabetes
• TRIUMPH-5 — The cardiovascular outcomes trial (CVOT). This is the one regulators and clinicians watch most closely, because it asks whether the metabolic improvements translate into reduced cardiovascular events.
• NAFLD/NASH sub-study — Effects on liver fat in people with non-alcoholic fatty liver disease, a condition for which there are very few effective treatments.
• Three further trials in obesity-related populations.

If TRIUMPH-5 reports positively — and on the strength of the existing data, it likely will — the case for retatrutide becoming the leading metabolic-health peptide of the decade is essentially complete. The remaining variable is then commercial: pricing, supply, and how quickly regulators move.

The bottom line for UK readers

Five things to take away if you came here to figure out whether to buy retatrutide now or wait:

1. The data is real. 28.3% average weight loss at 80 weeks, 45.3% past the 30% threshold, no plateau observed. This is the largest weight-loss outcome ever seen for a non-surgical treatment. Retatrutide is not "the next semaglutide" — it is a different generation.
2. The mechanism explains the numbers. Triple-receptor activity — particularly the glucagon arm — changes both appetite and energy expenditure. That is why the curve doesn't plateau the way it does with single or dual agonists.
3. UK availability is still 2–3 years away through the licensed route. Realistic MHRA approval is late 2027 or 2028; NICE adds another 6–18 months for NHS access. Private prescription will come before NHS — but if you want to buy retatrutide before 2028, the licensed route is not the answer.
4. The wellness-product route already exists in the UK. UK adults 18+ can buy retatrutide right now from brands like Retapen40, which sells UK-finished retatrutide pens with the structural trade-offs that come with the wellness-product market. If you're going to buy retatrutide via this route, see the buy guide first.
5. Seven more readouts are coming through 2026. The picture will sharpen significantly between now and the end of the year. Anyone making a decision now should keep an eye on TRIUMPH-5 specifically — the cardiovascular outcomes trial is the most consequential of the remaining seven.

FAQ

When were the TRIUMPH-1 results published?

Topline results were published by Eli Lilly on 21 May 2026. Full results will be presented at the 86th annual American Diabetes Association Scientific Sessions in June 2026, and subsequently published in peer-reviewed journals.

What was the average weight loss in TRIUMPH-1?

At the highest 12 mg dose, average body weight loss was 25.0% at 80 weeks on the standard reporting, rising to 28.3% on the efficacy estimand. In a 532-participant extension cohort with starting BMI ≥35, weight loss reached 30.3% at 104 weeks. 45.3% of 12 mg participants lost at least 30% of their body weight — a threshold previously associated with bariatric surgery.

How does retatrutide compare to Mounjaro and Wegovy?

In published trials, retatrutide consistently outperforms both. TRIUMPH-1's 28.3% sits above Mounjaro's best published ~22.5% and Wegovy's best published ~20.7%. Retatrutide also targets three receptor pathways (GLP-1 + GIP + glucagon) where Mounjaro targets two and Wegovy targets one. Full breakdown: retatrutide vs tirzepatide vs semaglutide.

When will retatrutide be available in the UK?

As of May 2026, retatrutide is not licensed in the UK and not available on the NHS. Realistic MHRA approval timelines point to late 2027 or 2028. NHS access via NICE technology appraisal would follow with a further 6–18 months delay. Private prescription access in the UK would likely begin first, shortly after MHRA approval.

What are the side effects of retatrutide?

Side effects are largely gastrointestinal and dose-dependent, in line with the rest of the GLP-1 class. From the TRANSCEND-T2D-1 trial: nausea (26.5% on highest dose), diarrhoea (22.8%), vomiting (17.6%). Discontinuation rates due to adverse events in TRIUMPH-1 were 4.1% at 4 mg, 6.9% at 9 mg and 11.3% at 12 mg, versus 4.9% on placebo. A small number of participants experienced dysesthesia, an unpleasant nerve sensation.

Will retatrutide be available on the NHS?

Eventually, yes — but with restrictions, and after a delay. NHS access requires both MHRA marketing authorisation and a positive NICE technology appraisal. Based on the pattern set by tirzepatide and semaglutide, initial NHS prescribing of retatrutide will likely be limited to patients meeting defined BMI and comorbidity criteria, with broader access phased in over subsequent years.

Can I buy retatrutide in the UK right now?

Not as a licensed medicine. You cannot buy retatrutide on the NHS, and you cannot buy retatrutide on a UK private prescription as of May 2026 — the MHRA has not yet granted marketing authorisation. However, you can buy retatrutide in the UK as a premium wellness product for adults aged 18 and over. The Reta Pen 40 is one such UK-finished retatrutide pen, shipped from London with cold-chain packaging and a 60-day satisfaction guarantee. Buyers confirm they are 18+ and UK-resident at checkout.

Where is the best place to buy retatrutide in the UK?

If you've decided to buy retatrutide via the UK wellness-product route, the six checks every UK buyer should run are: UK-finished pen, free tracked delivery, cold-chain packaging, real refund route, contactable support, transparent GBP pricing. A brand that clears all six is the calm way to buy. Our full UK buy guide covers each check in detail. The Reta Pen 40 is one example of a UK-finished pen that meets all six.

How much does it cost to buy retatrutide in the UK?

Pricing in the UK wellness-product market varies by plan size. At Retapen40, the Starter (one pen, 2-month supply) is £189; the Duo (two pens) is £349; the Buy 2 Get 1 FREE (three pens, 6-month supply) is £425; and the 12-Month Protocol (six pens) is £698 — which works out to £116.33 per pen, the lowest effective monthly rate to buy retatrutide in the UK on any current plan.

Is the weight loss permanent?

This is a question for which trial data is still emerging. Like other drugs in the GLP-1 class, retatrutide is designed as an ongoing treatment rather than a finite course. The clinical pattern observed with semaglutide and tirzepatide is that a significant proportion of weight is regained after discontinuation. Whether retatrutide follows the same pattern is still being studied.